EUVIMEDEUVIMED entdecken
Systematische Übersicht

Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review

Silvia Boeri iD, Luca Bosisio, Giulia Prato, Marina Martinez Popple, Elisa De Grandis, Pasquale Striano, Timothy A Benke, Lino Nobili

Journal of Child and Adolescent Psychopharmacology · 01.09.2026 · 36 (7) · 393-404

DOI: 10.1177/10445463261462382 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, online erschienen am 24.06.2026. Verfasst von Silvia Boeri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy. Hauptthemen laut MEDLINE: Fragile X Syndrome, Rett Syndrome, Autism Spectrum Disorder, Cannabinoids. Die Arbeit nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Neurodevelopmental disorders (NDDs), including Autism Spectrum Disorder (ASD), Fragile X syndrome (FXS), and Rett Syndrome (RTT), share impairments in cognitive and behavioral functioning and may involve an altered excitatory/inhibitory balance modulated by the endocannabinoid system. This systematic review evaluated the safety and efficacy of cannabinoid-based products (CBPs) in these pediatric NDDs.

Methods

We conducted a systematic review according to Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) 2020, including randomized and nonrandomized studies of patients under 18 years treated with cannabidiol (CBD), cannabidivarin (CBDV), tetrahydrocannabinol (THC), or their combinations. Outcomes were adverse events (AEs) and treatment discontinuation, seizure reduction, and behavioral and cognitive changes. Study quality and certainty of evidence were assessed using design-specific risk-of-bias tools and the GRADE approach.

Results

Seventeen studies (two randomized controlled trials, observational studies, and case series) met the inclusion criteria. Across diagnoses, CBPs were generally associated with mild-to-moderate AEs and low discontinuation rates. Descriptive pooled proportions suggested behavioral improvements in ASD and FXS and seizure reduction in RTT, with exploratory analyses indicating differential effects of CBD versus CBD + THC on behavioral and cognitive outcomes in ASD.

Conclusion

CBPs may offer potential benefits for selected behavioral symptoms and comorbid epilepsy in pediatric NDDs, but current evidence is insufficient to support routine clinical use. High-quality randomized controlled trials with standardized outcome measures and long-term follow-up are needed to clarify efficacy, safety, and syndrome-specific effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fragile X SyndromeRett SyndromeAutism Spectrum DisorderCannabinoidsHumansAdolescentChildDronabinolTreatment OutcomeCannabidiol

Stichwörter der Autor:innen

Autism Spectrum DisorderCannabidiolFragile X SyndromeRett SyndromeTetrahydrocannabinol

Substanzen

CannabinoidsDronabinolCannabidiol

Autor:innen und Institutionen

  • Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy.
  • Child Neuropsychiatry Unit, IRCCS Istituto Giannina Gaslini, Epicare Network for Rare Disease, Genoa, Italy.
  • Pediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
  • Department of Pediatrics, Neurology, and Pharmacology, University of Colorado School of Medicine/Children's Hospital Colorado, Aurora, Colorado, USA.

ORCID-Profile: Silvia Boeri

Zitieren

APA

Boeri, S., Bosisio, L., Prato, G., Martinez Popple, M., De Grandis, E., Striano, P., Benke, T. A., & Nobili, L. (2026). Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review. Journal of Child and Adolescent Psychopharmacology, 36(7), 393-404. https://doi.org/10.1177/10445463261462382

Vancouver

Boeri S, Bosisio L, Prato G, Martinez Popple M, De Grandis E, Striano P, et al. Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review. Journal of Child and Adolescent Psychopharmacology. 2026;36(7):393-404. doi:10.1177/10445463261462382

BibTeX
@article{Boeri2026,
  author = {Boeri, Silvia and Bosisio, Luca and Prato, Giulia and Martinez Popple, Marina and De Grandis, Elisa and Striano, Pasquale and Benke, Timothy A and Nobili, Lino},
  title = {Efficacy and Safety of Cannabinoid-Based Products in Children and Adolescents with Autism Spectrum Disorder, Fragile X Syndrome and Rett Syndrome: A Systematic Review},
  journal = {Journal of Child and Adolescent Psychopharmacology},
  year = {2026},
  volume = {36},
  number = {7},
  pages = {393--404},
  doi = {10.1177/10445463261462382}
}
Kostenlos starten →